Bachem Holding AG (BANB) AI Stock Analysis

• Market Cap: CHF4.15B
• Dividend Yield: 1.55%
• Average Volume (3M): 110.55K
• Price to Earnings (P/E): 34.5
• Beta (1Y): 1.30
• Revenue Growth: 4.84%
• EPS Growth: 7.45%
• Country: CH
• Employees: 2,207
• Sector: Healthcare
• Sector Strength: 58
• Industry: Chemicals
• EPS (TTM): 1.12
• Shares Outstanding: 75,000,000
• 10 Day Avg. Volume: 120,866
• 30 Day Avg. Volume: 110,553
• PEG Ratio: -3.79
• Price to Book (P/B): 5.03
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -118.33
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: CHF71.50
• Price Target Upside: 31.80% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 76 Outperform
• Price Target: CHF60.00 ▲(10.60%Upside)

Bachem Holding AG scores well due to its strong financial performance, supported by solid revenue growth and stable profitability metrics. The technical indicators suggest positive momentum, though the high P/E ratio indicates potential overvaluation. The absence of recent earnings call details or notable corporate events limits further insights into immediate operational strategies.

Bachem Holding AG Business Overview & Revenue Model

Company Description

Bachem Holding AG provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. The company engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). It also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, and supply and vertical integration services. The company was founded in 1971 and is headquartered in Bubendorf, Switzerland. Bachem Holding AG operates as a subsidiary of Ingro Finanz AG.

How the Company Makes Money

Bachem Holding AG generates revenue primarily through the production and sale of peptides and oligonucleotides, which are essential components in pharmaceutical research and development. The company's key revenue streams include custom synthesis services, where they manufacture these molecules according to client specifications, and catalog products, which are standard offerings for research and development purposes. Bachem collaborates with pharmaceutical companies, biotech firms, and academic institutions, leveraging its advanced production capabilities to support drug development pipelines. Additionally, strategic partnerships and long-term supply agreements with major pharmaceutical companies contribute significantly to its revenue, ensuring a stable and recurring income stream.

Bachem Holding AG Financial Statement Overview

Summary

Bachem Holding AG demonstrates strong financial performance with consistent revenue growth, stable gross profit margins, and healthy net profit margins. The balance sheet reflects low leverage and a robust capital structure, while cash flow management is strong despite recent high capital expenditures impacting free cash flow.

Income Statement

Bachem Holding AG has shown a strong revenue growth rate with revenues increasing consistently year over year. The gross profit margin is stable, indicating good control over production costs. Net profit margins are healthy, supported by increasing net income over the past few years. EBIT and EBITDA margins are strong, showcasing efficient operations. The company has demonstrated solid growth and profitability in the medical pharmaceuticals sector.

Balance Sheet

The company maintains a low debt-to-equity ratio, reflecting low leverage and financial stability. The return on equity is robust, indicating effective use of equity to generate profits. The equity ratio is high, underscoring a strong capital structure. Bachem has increased its total assets significantly, primarily funded by equity, which reduces potential risks associated with high leverage.

Cash Flow

Bachem Holding AG exhibits strong operating cash flow relative to net income, indicating effective cash generation from operations. However, the free cash flow has been negative recently due to high capital expenditures, which could limit liquidity in the short term. Despite this, the company's investment in growth seems to be strategically driven.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
605.26M	577.32M	531.74M	503.23M	402.00M
	Gross Profit
182.56M	176.96M	171.28M	166.73M	128.91M
	EBIT
133.05M	129.38M	126.31M	128.04M	95.80M
	EBITDA
178.76M	163.28M	157.08M	156.47M	121.72M
	Net Income Common Stockholders
120.25M	111.86M	100.68M	114.68M	78.06M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
95.20M	298.53M	268.43M	442.36M	23.50M
	Total Assets
1.92B	1.68B	1.38B	1.30B	710.88M
	Total Debt
290.00K	401.00K	691.00K	20.86M	107.55M
	Net Debt
-94.91M	-157.32M	-30.76M	-68.33M	84.06M
	Total Liabilities
531.88M	362.36M	214.21M	177.50M	235.17M
	Stockholders Equity
1.39B	1.32B	1.17B	1.12B	475.71M
Cash Flow		Free Cash Flow
-138.30M	-18.54M	-49.76M	-19.66M	45.53M
	Operating Cash Flow
146.32M	249.86M	92.59M	97.16M	114.63M
	Investing Cash Flow
-148.88M	-170.81M	-63.17M	-469.13M	-69.31M
	Financing Cash Flow
-61.26M	48.69M	-86.93M	437.58M	-42.66M

Bachem Holding AG Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 54.25
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:BANB, the sentiment is Positive. The current price of 54.25 is above the 20-day moving average (MA) of 52.06, above the 50-day MA of 49.96, and below the 200-day MA of 59.89, indicating a neutral trend. The MACD of 1.10 indicates Negative momentum. The RSI at 60.13 is Neutral, neither overbought nor oversold. The STOCH value of 78.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CH:BANB.

Bachem Holding AG Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BANB	76 Outperform	CHF4.15B	34.48	8.87%	1.55%	4.84%	7.45%
Sector *	54 Neutral	$5.41B	3.27	-45.10%	3.29%	16.81%	0.02%
0RGI		CHF1.01B	7.58	29.55%	3.19%	―	―
SGFEF		$5.39B	26.06	18.36%	0.42%	―	―
TCHBF		$2.71B	34.25	4.84%	1.74%	―	―
PPGN	61 Neutral	CHF701.91M	―		―	3.15%	62.88%
GALE		CHF4.24B	23.33		2.69%	―	―

Bachem Holding AG Corporate Events

Bachem Mourns the Passing of Founder Peter Grogg

Bachem mourns the loss of its founder, Dr. h.c. Peter Grogg, who passed away at 83. Grogg, who founded the company in 1971, was instrumental in transforming Bachem into a world leader in peptide synthesis, leaving a significant mark on the firm and Swiss economic history. His leadership spanned over three decades, during which he served as CEO and later as chairman of the board. The announcement highlights the deep impact Grogg had on Bachem’s operations and its standing in the industry.

The most recent analyst rating on (CH:BANB) stock is a Buy with a CHF100.00 price target. To see the full list of analyst forecasts on Bachem Holding AG stock, see the CH:BANB Stock Forecast page.

Bachem’s AGM 2025 Approves Board Proposals and Dividend

Bachem Holding AG announced that its Annual General Meeting 2025 approved all proposals from the Board of Directors, including a dividend of CHF 0.85 per share, to be paid on May 7, 2025. The meeting also saw the re-election of the President and Board members, the election of Dr. Simone Wyss Fedele to the Board, and the approval of various financial and sustainability reports. Forvis Mazars SA was appointed as the auditor for 2025. This approval reflects strong shareholder support and positions Bachem for continued stability and growth in the pharmaceutical and biotech sectors.

Bachem Proposes New Board Member with Extensive Life Sciences Experience

Bachem Holding AG announced the proposal of Dr. Simone Wyss Fedele, CEO of Switzerland Global Enterprise, for election as a new member of its Board of Directors at the upcoming General Meeting in April 2025. Dr. Fedele brings extensive experience in the life sciences industry and international trade, having held leadership roles at Novartis and Takeda Pharmaceuticals. Her addition is expected to enhance Bachem’s strategic positioning and strengthen its board with her international expertise and connections.